ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced results of preclinical studies, which suggest that
pimavanserin, ACADIA's proprietary product candidate currently in Phase
III development for Parkinson's disease psychosis, also may have
therapeutic benefits in the treatment of Alzheimer's disease psychosis
(ADP). Results of these studies were published in the scientific
journal, Behavioural Pharmacology (Price et al., "Pimavanserin, a
5-HT2A Receptor Inverse Agonist, Reverses Psychosis-like
Behaviors in a Rodent Model of Alzheimer's Disease," July 2012 e-pub).
ACADIA scientists reported results of experiments using mice that had
received intracerebroventricular (ICV) infusion of an amyloid β peptide
fragment and developed Alzheimer's disease-like pathology. These animals
developed psychosis-like behaviors with enhanced responses to the
psychostimulants DOI and amphetamine as well as disrupted prepulse
inhibition. Treatment with pimavanserin prevented DOI-induced responses,
reversed the augmented responses to amphetamine, and normalized prepulse
inhibition in animals with amyloid pathology. These findings suggest
that 5-HT2A antagonists/inverse agonists, such
as pimavanserin, may be effective in the treatment of patients with ADP.
"ADP represents a major unmet medical need with no proven safe and
effective therapy," said Uli Hacksell, Ph.D., ACADIA's Chief Executive
Officer. "Physicians often resort to off-label use of antipsychotic
medications in patients with ADP despite their association with
increased mortality and potential worsening of cognitive disturbances.
These new findings suggest that pimavanserin may be ideally suited to
address the need for a new ADP treatment that is safe, effective and
ACADIA Pharmaceuticals Inc.